Enveric Biosciences, Inc.
ENVB
$1.27
$0.010.79%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 30.74% | -51.37% | -10.89% | 23.51% | 28.49% |
| Total Depreciation and Amortization | -1.82% | -2.71% | 0.00% | -0.70% | 1.07% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -78.34% | 138.60% | 5.47% | 6.33% | -76.33% |
| Change in Net Operating Assets | -154.59% | 24.99% | 148.55% | -159.58% | -370.60% |
| Cash from Operations | -82.36% | -41.46% | 67.91% | -11.20% | -48.39% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 819.57% | -6.57% | 702.79% | -98.71% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -20,300.00% | 99.67% | -101.80% | 999.30% |
| Cash from Financing | 860.06% | -10.49% | 1,404.94% | -99.48% | 3,677.81% |
| Foreign Exchange rate Adjustments | 82.74% | -222.16% | 1,323.08% | -83.95% | 119.57% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 335.83% | -122.74% | 86.30% | -170.14% | 305.60% |